Company Profile
Celcuity Stock Price, News & Catalysts
- Ticker:
- CELC
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
92.44 USD (+0.48%)
Close
Last updated: August 17, 2026
4.46B USD
Market cap
Why the stock is moving
As of Aug 17, 2026, CELC closed up 0.48% at $92.44. No new same-company headline was identified in the current news window.
Company overview
PAM Pathway Oncology
Celcuity develops targeted therapies that inhibit the PI3K-AKT-mTOR signaling network, a pathway frequently involved in treatment resistance and tumor growth.
REVTORPYK
REVTORPYK, or gedatolisib, is an FDA-approved pan-PI3K and mTORC1/2 inhibitor for certain patients with hormone-receptor-positive, HER2-negative, PIK3CA wild-type advanced breast cancer.
VIKTORIA-1
The Phase 3 VIKTORIA-1 program evaluates gedatolisib combinations after progression on endocrine therapy. Positive results in both PIK3CA wild-type and mutant cohorts support expansion of the approved population.
First-Line Development
VIKTORIA-2 evaluates gedatolisib regimens in the first-line advanced breast-cancer setting, including endocrine-sensitive and endocrine-resistant patient populations.
Future catalysts
- Submission of an sNDA for REVTORPYK in PIK3CA-mutant advanced breast cancer in the third quarter of 2026.
- Commercial launch of REVTORPYK in late third-quarter 2026.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Celcuity (CELC)?
Celcuity (CELC) most recently closed at 92.44 USD, a +0.48% move versus the previous session.
What is the market cap of Celcuity (CELC)?
Celcuity currently has a market capitalization of 4.46B USD on BioPharmSignal.
What does Celcuity do?
PAM Pathway Oncology Celcuity develops targeted therapies that inhibit the PI3K-AKT-mTOR signaling network, a pathway frequently involved in treatment resistance and tumor growth. REVTORPYK REVTORPYK, or gedatolisib, is an FDA-approved pan-PI3K and mTORC1/2 inhibitor for certain patients with hormone-receptor-positive, HER2-negative, PIK3CA wild-type...
On which exchange is CELC stock listed?
Celcuity (CELC) is associated with NASDAQ, United States, Biopharma.
What is VIKTORIA-1?
VIKTORIA-1 The Phase 3 VIKTORIA-1 program evaluates gedatolisib combinations after progression on endocrine therapy.
Which conditions is Celcuity targeting with VIKTORIA-1?
Celcuity is associated with oncology, cancer therapeutics based on its company overview and current catalyst commentary.
How does Celcuity describe recent progress with VIKTORIA-1?
Submission of an sNDA for REVTORPYK in PIK3CA-mutant advanced breast cancer in the third quarter of 2026. Commercial launch of REVTORPYK in late third-quarter 2026.
What is VIKTORIA-2?
First-Line Development VIKTORIA-2 evaluates gedatolisib regimens in the first-line advanced breast-cancer setting, including endocrine-sensitive and endocrine-resistant patient populations.